Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority to CU20100127ApriorityCriticalpatent/CU20100127A7/en
Publication of CU20100127A7publicationCriticalpatent/CU20100127A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I): y sus sales, en donde los sustituyentes son como los definidos en la descripción; a composiciones y uso de los compuestos en el tratamiento de enfermedades mejoradas por la inhibición de la fosfaditilinositol 3-cinasa.The present invention relates to compounds of the formula (I): and their salts, wherein the substituents are as defined in the description; to compositions and use of the compounds in the treatment of diseases enhanced by the inhibition of phosphatitylinositol 3-kinase.
CU20100127A2010-06-182010-06-18
TIAZOL DERIVATIVES USED AS PI 3-CINASA INHIBITORS
CU20100127A7
(en)
DERIVATIVES OF 2-CARBOXAMIDE - CICLOAMINO - UREA SPECIFIC, ITS PHARMACUTICALLY ACCEPTABLE SALTS, COMPOSITIONS CONTAINING THEM, PRO-PHARMACES OF THE SAME, PROCESSES FOR PRODUCTION AND APPLICATIONS